A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
Clinical trial NCT06625593 · RECRUITING
Trial details
- NCT number
- NCT06625593
- Sponsor
- BeOne Medicines
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-09
- Primary completion
- 2026-12-31
- Enrollment
- 168
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.